Olema Pharmaceuticals, Inc. (OLMA)
Largest Insider Buys in Sector
OLMA Stock Price History Chart
OLMA Stock Performance
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema …
Insider Activity of Olema Pharmaceuticals, Inc.
Over the last 12 months, insiders at Olema Pharmaceuticals, Inc. have bought $9.46M and sold $66.7M worth of Olema Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Olema Pharmaceuticals, Inc. have bought $28.57M and sold $19.42M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Graham G. Walmsley (director) — $28.38M.
The last purchase of 700,761 shares for transaction amount of $4.73M was made by Graham G. Walmsley (director) on 2024‑12‑17.
List of Insider Buy and Sell Transactions, Olema Pharmaceuticals, Inc.
| 2024-12-17 | Sale | director | 700,761 1.3522% | $6.75 | $4.73M | -0.65% | ||
| 2024-12-17 | director | 700,761 1.3522% | $6.75 | $4.73M | -0.65% | |||
| 2024-12-13 | Sale | director | 700,761 1.2508% | $6.75 | $4.73M | -9.04% | ||
| 2024-12-13 | director | 700,761 1.2508% | $6.75 | $4.73M | -9.04% | |||
| 2024-12-11 | Sale | director | 8,137 0.0148% | $8.68 | $70,597 | -23.42% | ||
| 2024-12-11 | Sale | CH. DISCOV. & NON-CLIN DEV OFF | 13,614 0.0247% | $8.68 | $118,116 | -23.42% | ||
| 2024-12-11 | Sale | CH. OPERATING & FINANCIAL OFF. | 18,356 0.0333% | $8.68 | $159,259 | -23.42% | ||
| 2024-12-11 | Sale | PRESIDENT AND CEO | 57,174 0.1037% | $8.68 | $496,052 | -23.42% | ||
| 2024-12-11 | Sale | CHIEF MEDICAL OFFICER | 14,522 0.0264% | $8.68 | $125,994 | -23.42% | ||
| 2024-12-10 | Sale | director | 8,256 0.0145% | $9.37 | $77,359 | -31.74% | ||
| 2024-12-10 | Sale | CH. DISCOV. & NON-CLIN DEV OFF | 12,452 0.0218% | $9.38 | $116,800 | -31.74% | ||
| 2024-12-10 | Sale | CH. OPERATING & FINANCIAL OFF. | 16,803 0.0294% | $9.37 | $157,444 | -31.74% | ||
| 2024-12-10 | Sale | PRESIDENT AND CEO | 52,328 0.0917% | $9.37 | $490,313 | -31.74% | ||
| 2024-12-10 | Sale | CHIEF MEDICAL OFFICER | 13,283 0.0233% | $9.37 | $124,462 | -31.74% | ||
| 2024-08-01 | Sale | 10 percent owner | 2.4M 3.888% | $14.91 | $35.8M | -28.71% | ||
| 2024-07-30 | Sale | director | 934 0.0017% | $15.55 | $14,524 | +5.85% | ||
| 2024-07-29 | Sale | director | 4,066 0.0075% | $15.58 | $63,348 | -22.71% | ||
| 2024-07-11 | Sale | director | 5,000 0.0099% | $12.26 | $61,300 | 0.00% | ||
| 2024-06-28 | Sale | director | 20,000 0.0348% | $10.77 | $215,400 | 0.00% | ||
| 2024-06-04 | Sale | director | 5,000 0.0079% | $12.33 | $61,650 | -15.13% |
Insider Historical Profitability
| Graham G. Walmsley | director | 1408875 2.4589% | $6.10 | 5 | 3 | <0.0001% |
| Paradigm Biocapital Advisors LP | 10 percent owner | 783118 1.3668% | $6.10 | 1 | 1 | |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 543549 0.9486% | $6.10 | 2 | 4 | +244.38% |
| BVF PARTNERS L P/IL | 4688954 8.1835% | $6.10 | 3 | 0 | <0.0001% | |
| Cormorant Asset Management, LP | 3270544 5.708% | $6.10 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $103.42M | 16.33 | 9.14M | 0% | +$0 | 0.76 | |
| Paradigm BioCapital Advisors LP | $89.47M | 14.13 | 7.9M | 0% | +$0 | 3.25 | |
| Logos Global Management Lp | $49.63M | 7.84 | 4.38M | 0% | +$0 | 5.36 | |
| Deep Track Capital Lp | $36.51M | 5.77 | 3.23M | +67.04% | +$14.65M | 0.17 | |
| BlackRock | $36.41M | 5.75 | 3.22M | -1.45% | -$536,035.96 | <0.01 |